Mitral valve articles

TCT 2022

TCT 2022 | Edge-to-Edge Repair in Patients with Severe Mitral Insufficiency and Cardiogenic Shock: Analysis of the TVT Registry

TCT 2022 | Edge-to-Edge Repair in Patients with Severe Mitral Insufficiency and Cardiogenic Shock: Analysis of the TVT Registry

Approximately 1 in 5 patients admitted for cardiogenic shock (CS) were observed to have moderate to severe mitral insufficiency (MI), which increases the risk of mortality by about 60%. To date, there is limited data on the role of transcatheter edge-to-edge repair therapy in this setting. The aim of this study was to describe the

Highlights SOLACI-SOCIME 2022

SOLACI-SOCIME 2022 | When is indicated the transcatheter treatment of mitral regurgitation

Read the most outstanding articles from the first day of the SOLACI-SOCIME 2022 Congress. In this case, consult the presentation by Dr. Márcio Montenegro, entitled “When is indicated the transcatheter treatment of mitral regurgitation”

The Best of Main Arena - SOLACI-SOCIME 2022

The Best of the SOLACI-SOCIME 2022 Main Arena: Mitral Valve

During the “Mitral Valve” session (on the first day of the SOLACI-SOCIME 2022 Congress), Dr. Ignacio Amat Santos (SPA) delivered a great talk on transcatheter mitral valve replacement (TMVR). During his presentation, he discussed different scenarios for transcatheter replacement: mitral valve-in-vale, mitral valve-in-ring, mitral valve in MAC, and new devices for non-calcified native valves.  When

Post-MitraClip Mitral Valve Stenosis: Bad Prognosis

The EVEREST II trial has shown the MitraClip has similar mortality rate to that of surgery and, on the other hand, we are well aware that residual mitral regurgitation (MR) is associated with a strong negative impact. However, research has shown little about transvalvular gradient after MitraClip and what it entails. 268 patients receiving MitraClip were

La reparación de la válvula mitral con Mitraclip es segura en pacientes de alto riesgo

MitraClip Reduces Renal Function Deterioration

Severe mitral regurgitation is associated to cardiac failure and hospitalization and over time is accompanied by kidney failure, which leads to higher mortality.  In the COAPT study, in patients with low ejection fraction, MitraClip showed benefits over medical treatment, but there was an important group of people with kidney function deterioration.  The evolution and benefit

Is High Mean Gradient After Edge-to-Edge Strategy Important?

Edge-to-edge treatment of the mitral valve is currently a valid alternative to surgery in cases of mitral regurgitation. Different studies have taken residual mitral regurgitation as a parameter of success, but little research has been conducted on the residual gradient once the procedure has been completed.  What has been published is that a mean gradient

Estenosis aórtica severa asintomática en añosos: ¿cuándo intervenir?

Transcatheter Edge-To-Edge Repair Is Favorable for Elderly Patients at High Surgical Risk

Mitral valve prolapse is the most frequent cause of mitral valve regurgitation and is associated to hospitalization for cardiac failure and mortality. At present, the preferred treatment for operable patients is mitral valve surgical repair. Transcatheter edge to edge repair (TEER) has shown great benefit patients at high surgical risk; however, it has not been

Is Increased Mitral Valve Gradient After MitraClip a Long-Term Prognostic Factor?

Transcatheter mitral valve repair using the edge-to-edge strategy has become a therapeutic alternative for patients with severe primary mitral valve regurgitation (MVG) who are at high or extreme surgical risk. However, both degree of residual regurgitation and gradient after the procedure should be taken into account, as in previous studies the latter was associated with

MitraClip Failure: What Should We Do?

Currently, edge-to-edge therapy with MitraClip has demonstrated efficacy and safety for the treatment of patients with degenerative or functional mitral regurgitation  who are at high risk for surgery. However, device-related complications are still present—though their frequency is subsiding due to greater experience, 3D doppler echocardiography development, and technological advancements: loss of leaflet insertion (LLI), single

Nuevas guías de valvulopatías con actualizaciones clave en TAVI e insuficiencia mitral

New Valvular Heart Disease Guidelines with Key TAVI and Mitral Regurgitation Updates

Valvular heart disease management guidelines were updated last week by the AHA and the ACC.  The last complete version had been published in 2014; therefore many of its recommendations have become obsolete before the latest evidence.  The studies that made the FDA approve TAVI for low-risk patients are probably the most important incorporations. They also

Top